Inside the Race to Build AI Defenses Against Bioweapons
Summary
WSJ reporter Georgia Wells explores the growing risk that AI could lower barriers to engineering biological weapons, citing recent attempts to synthesize pathogens via chatbots. The episode profiles Red Queen Bio, an OpenAI-backed startup using AI to rapidly design antibody treatments for emerging viruses like bird flu and coronaviruses. Host Isabel Busquet discusses the company's origins, its $15 million funding, and the broader "Red Queen" dynamic where defenders must constantly adapt to keep pace with attackers.
Topics discussed
Sponsor and schedule update
Intro: Can AI create the next pandemic?
The threat: AI-assisted bioweapons and Red Queen Bio
Evidence of malicious AI use by users
Red Queen Bio's antibody defense strategy
Developing cures for non-existent diseases
Company origins and funding details
Other AI biosecurity startups
Segment break and recap
Founder Hanu Ryanemi's personal motivation
Origin of the name Red Queen Bio
Attacker vs. Defender advantage analysis
Conclusion and credits
Promo: WSJ Future of Health event
Listen ad-free on Castria